CL2013002185A1 - Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih. - Google Patents

Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.

Info

Publication number
CL2013002185A1
CL2013002185A1 CL2013002185A CL2013002185A CL2013002185A1 CL 2013002185 A1 CL2013002185 A1 CL 2013002185A1 CL 2013002185 A CL2013002185 A CL 2013002185A CL 2013002185 A CL2013002185 A CL 2013002185A CL 2013002185 A1 CL2013002185 A1 CL 2013002185A1
Authority
CL
Chile
Prior art keywords
compounds
inhibitors
pharmaceutical composition
hiv
intermediary
Prior art date
Application number
CL2013002185A
Other languages
English (en)
Spanish (es)
Inventor
Yan Chen
Alicia Regueiro-Ren
Zheng Liu
Ny Sin
Brian Lee Venables
Sing-Yuen Sit
Jie Chen
Nicholas A Meanwell
Jacob Swidorski
Original Assignee
Viiv Healthcare Uk No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 4 Ltd filed Critical Viiv Healthcare Uk No 4 Ltd
Publication of CL2013002185A1 publication Critical patent/CL2013002185A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013002185A 2011-01-31 2013-07-30 Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih. CL2013002185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31

Publications (1)

Publication Number Publication Date
CL2013002185A1 true CL2013002185A1 (es) 2013-12-27

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002185A CL2013002185A1 (es) 2011-01-31 2013-07-30 Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.

Country Status (25)

Country Link
US (3) US8846647B2 (cg-RX-API-DMAC7.html)
EP (1) EP2670765B1 (cg-RX-API-DMAC7.html)
JP (1) JP6001560B2 (cg-RX-API-DMAC7.html)
KR (1) KR101886467B1 (cg-RX-API-DMAC7.html)
CN (1) CN103429607B (cg-RX-API-DMAC7.html)
AR (1) AR085053A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012212509B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013019419A2 (cg-RX-API-DMAC7.html)
CA (1) CA2826113C (cg-RX-API-DMAC7.html)
CL (1) CL2013002185A1 (cg-RX-API-DMAC7.html)
CO (1) CO6751275A2 (cg-RX-API-DMAC7.html)
EA (1) EA022470B1 (cg-RX-API-DMAC7.html)
ES (1) ES2653847T3 (cg-RX-API-DMAC7.html)
IL (1) IL227678B (cg-RX-API-DMAC7.html)
MA (1) MA34909B1 (cg-RX-API-DMAC7.html)
MY (1) MY162186A (cg-RX-API-DMAC7.html)
PE (1) PE20141152A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501528A1 (cg-RX-API-DMAC7.html)
PT (1) PT2670765T (cg-RX-API-DMAC7.html)
SG (1) SG192144A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000321A1 (cg-RX-API-DMAC7.html)
TW (1) TWI628188B (cg-RX-API-DMAC7.html)
UY (1) UY33886A (cg-RX-API-DMAC7.html)
WO (1) WO2012106190A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306546B (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009237579C1 (en) 2008-04-18 2016-05-12 Reata Pharmaceuticals Holdings, LLC Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
BRPI0911208B1 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals, Inc Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica
JP5588966B2 (ja) 2008-04-18 2014-09-10 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17同族体化オレアノール酸誘導体
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
KR102000301B1 (ko) 2010-12-17 2019-07-15 리아타 파마슈티컬즈, 아이엔씨. 산화방지성 염증 조절제로서의 피라졸릴 및 피리미디닐 트리사이클릭 엔온
CN103339141B (zh) * 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
PT2683731T (pt) 2011-03-11 2019-07-12 Reata Pharmaceuticals Inc Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos
US8754069B2 (en) 2011-09-21 2014-06-17 Bristol-Myers Squibb Company Betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PE20150160A1 (es) 2012-04-27 2015-02-19 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9273001B2 (en) * 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
HRP20191165T1 (hr) 2012-09-10 2019-10-04 Reata Pharmaceuticals, Inc. C17-alkandiilni i alkendiilni derivati oleanolne kiseline i postupci njihove upotrebe
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
EA027861B1 (ru) * 2013-02-25 2017-09-29 Бристол-Майерс Сквибб Компани C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе
SMT202000581T1 (it) 2014-04-11 2020-11-10 Viiv Healthcare Uk No 4 Ltd Triterpenoidi con attività di inibizione della maturazione di hiv, sostituiti in posizione 3 con un anello non aromatico portante un sostituente alogenoalchilico
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
WO2016077569A1 (en) 2014-11-14 2016-05-19 Bristol-Myers Squibb Company C17-aryl substituted betulinic acid analogs
US20180094019A1 (en) * 2015-04-14 2018-04-05 ViiV Healthcare UK (No.4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
WO2017053868A1 (en) 2015-09-23 2017-03-30 Reata Pharmaceutical, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
JP2018528231A (ja) 2015-09-24 2018-09-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有する化合物
RU2018116772A (ru) 2015-11-20 2019-12-20 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Композиции ингибитора созревания ВИЧ
CA3011616A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
SG11202000950TA (en) 2017-08-04 2020-02-27 Ardelyx Inc Glycyrrhetinic acid derivatives for treating hyperkalemia
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
MX2021009491A (es) 2019-02-07 2021-09-08 Ardelyx Inc Compuestos y metodos para tratar la hiperpotasemia.
US12275712B2 (en) 2019-02-11 2025-04-15 Hetero Labs Limited Triterpene derivatives as HIV inhibitors
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
RS54239B1 (sr) * 2010-06-04 2015-12-31 Bristol-Myers Squibb Company C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a

Also Published As

Publication number Publication date
PE20141152A1 (es) 2014-09-22
US20140343000A1 (en) 2014-11-20
BR112013019419A2 (pt) 2019-12-03
AU2012212509B2 (en) 2016-01-21
AR085053A1 (es) 2013-08-07
CN103429607B (zh) 2016-02-17
US8846647B2 (en) 2014-09-30
CN103429607A (zh) 2013-12-04
CA2826113C (en) 2018-09-04
MY162186A (en) 2017-05-31
SG192144A1 (en) 2013-08-30
KR101886467B1 (ko) 2018-08-07
EA022470B1 (ru) 2016-01-29
MA34909B1 (fr) 2014-02-01
UY33886A (es) 2012-07-31
EP2670765B1 (en) 2017-10-18
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
CO6751275A2 (es) 2013-09-16
TWI628188B (zh) 2018-07-01
JP6001560B2 (ja) 2016-10-05
IL227678B (en) 2018-04-30
AU2012212509A1 (en) 2013-09-19
CA2826113A1 (en) 2012-08-09
EP2670765A1 (en) 2013-12-11
KR20140016279A (ko) 2014-02-07
EA201391127A1 (ru) 2013-12-30
JP2014503595A (ja) 2014-02-13
PH12013501528A1 (en) 2013-09-16
TW201309717A (zh) 2013-03-01
US20130035318A1 (en) 2013-02-07
TN2013000321A1 (en) 2015-01-20
IL227678A0 (en) 2013-09-30
PT2670765T (pt) 2018-01-08
ES2653847T3 (es) 2018-02-09
NZ614871A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
CL2013002185A1 (es) Compuestos derivados de terpenos modificados en c-17 y c3, inhibidores de la maduración del vih; compuestos intermediarios; composición farmacéutica que los comprende; su uso para tratar la infección por vih.
CL2019002204A1 (es) Compuestos inhibidores del vih.
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
PE20151067A1 (es) Inhibidores de autotaxina
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
MX2017012558A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
GT201300254A (es) Triazolopiridinas
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
CO7170160A2 (es) Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
DOP2014000133A (es) Triazolopiridinas sustituidas
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2012000256A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич